Company news

Keros Therapeutics, Inc. news in 2024

Keros Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

December 11, 2024

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

December 8, 2024

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

December 2, 2024

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

November 5, 2024

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

November 5, 2024

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

November 4, 2024

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

October 15, 2024

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

September 11, 2024

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

September 2, 2024

Keros Therapeutics Reports Second Quarter 2024 Financial Results

August 6, 2024

Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

June 16, 2024

Keros Therapeutics Announces Leadership Updates

June 16, 2024

Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

June 3, 2024

Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 2, 2024

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

May 27, 2024

Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

May 13, 2024

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

May 7, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

March 13, 2024

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

March 4, 2024

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

January 28, 2024

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

January 8, 2024

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

January 2, 2024

Keros Therapeutics Announces Proposed Public Offering of Common Stock

January 2, 2024

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

January 2, 2024

Decks in 2024